Caspofungin etest susceptibility testing of Candida species: Risk of misclassification of susceptible isolates of C. glabrata and C. krusei when adopting the revised CLSI caspofungin breakpoints

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 7, 2012, Pages 3965-3968

  Arendrup, Maiken Cavling ^a   Pfaller, Michael A ^b   Arendrup, M C ^a   Dzajic, E ^c,d   Johansen, H K ^e   Kjaeldgaard P ^f   Knudsen, J D ^g   Kristensen, L ^h   Leitz, C ⁱ   Lemming, L E ^j   Nielsen, L ^k   Olesen, B ^l   Rosenvinge, F S ^m   Roder B L ⁿ   Schonheyder H C ^o  

^a STATENS SERUM INSTITUT   (Denmark)

^b UNIVERSITY OF IOWA   (United States)

^c ESBJERG HOSPITAL   (Denmark)

^d LILLEBAELT HOSPITAL   (Denmark)

^e International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

^f Sonderborg Hospital   (Denmark)

^g HVIDOVRE HOSPITAL   (Denmark)

^h HERNING HOSPITAL   (Denmark)

ⁱ Sydvestjysk Sygehus   (Denmark)

^j AARHUS UNIVERSITY HOSPITAL   (Denmark)

^k GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^l HILLERØD HOSPITAL   (Denmark)

^m ODENSE UNIVERSITY HOSPITAL   (Denmark)

ⁿ SLAGELSE HOSPITAL   (Denmark)

^o AALBORG UNIVERSITY HOSPITAL   (Denmark)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANIDULAFUNGIN; CASPOFUNGIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BLOOD SAMPLING; BROTH DILUTION; CANDIDA; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CODING AND CLASSIFICATION; CONTROLLED STUDY; EPSILOMETER TEST; FUNGAL STRAIN; FUNGUS ISOLATION; MINIMUM INHIBITORY CONCENTRATION; MISCLASSIFICATION; NONHUMAN; PRIORITY JOURNAL; RISK FACTOR; VIRUS RESISTANCE; WILD TYPE;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDA GLABRATA; CANDIDIASIS; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; MICROBIAL SENSITIVITY TESTS;

EID: 84862513977     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00355-12     Document Type: Article

References (22)

1. Arendrup MC, et al. 2009. Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. Antimicrob. Agents Chemother. 53:1185-1193.
2. Arendrup MC, et al. 2010. Echinocandin susceptibility testing of Candida species: comparison of EUCAST EDef 7.1, CLSI M27-A3, Etest, disk diffusion, and agar dilution methods with RPMI and IsoSensitest media. Antimicrob. Agents Chemother. 54:426-439.
3. Arendrup MC, et al. 2011. EUCAST technical note on anidulafungin. Clin. Microbiol. Infect. 17:E18-E20.
4. Arendrup MC, et al. 2011. Echinocandin susceptibility testing of Candida spp. using the EUCAST EDef 7.1 and CLSI M27-A3 standard procedures: analysis of the influence of bovine serum albumin supplementation, storage time, and drug lots. Antimicrob. Agents Chemother. 55:1580-1587.
5. Axner-Elings M, Botero-Kleiven S, Jensen RH, Arendrup MC. 2011. Echinocandin susceptibility testing of Candida isolates collected during a 1-year period in Sweden. J. Clin. Microbiol. 49:2516-2521.
6. Baixench MT, et al. 2007. Acquired resistance to echinocandins in Candida albicans: case report and review. J. Antimicrob. Chemother. 59:1076-1083.
7. Chryssanthou E, Cuenca-Estrella M. 2002. Comparison of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antibiotic Susceptibility Testing proposed standard and the E-test with the NCCLS broth microdilution method for voriconazole and caspofungin susceptibility testing of yeast species. J. Clin. Microbiol. 40:3841-3844.
8. Garcia-Effron G, Kontoyiannis DP, Lewis RE, Perlin DS. 2008. Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies. Antimicrob. Agents Chemother. 52:4181-4183.
9. Garcia-Effron G, Lee S, Park S, Cleary JD, Perlin DS. 2009. Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-β-D-glucan synthase: implication for the existing susceptibility breakpoint. Antimicrob. Agents Chemother. 53:3690-3699.
10. Garcia-Effron G, Park S, Perlin DS. 2009. Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. Antimicrob. Agents Chemother. 53:112-122.
11. Garcia-Effron G, Park S, Perlin DS. 2011. Improved detection of Candida sp. fks hot spot mutants by using the method of the CLSI M27-A3 document with the addition of bovine serum albumin. Antimicrob. Agents Chemother. 55:2245-2255.
12. Hakki M, Staab JF, Marr KA. 2006. Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy. Antimicrob. Agents Chemother. 50:2522-2524.
13. Laverdiere M, Restieri C, Habel F. 2002. Evaluation of the in vitro activity of caspofungin against bloodstream isolates of Candida species from cancer patients: comparison of Etest and NCCLS reference methods. Int. J. Antimicrob. Agents 20:468-471.
14. Pfaller MA, et al. 2010. Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp. J. Clin. Microbiol. 48:52-56.
15. Pfaller MA, et al. 2010. Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Etest methods with the CLSI broth microdilution method for echinocandin susceptibility testing of Candida species. J. Clin. Microbiol. 48:1592-1599.
16. Pfaller MA, et al. 2011. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist. Updat. 14:164-176.
17. Pfeiffer CD, et al. 2010. Breakthrough invasive candidiasis in patients on micafungin. J. Clin. Microbiol. 48:2373-2380.
18. Rodriguez-Tudela JL, et al. 2008. EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clin. Microbiol. Infect. 14:398-405.
19. Slater JL, et al. 2011. Disseminated candidiasis caused by Candida albicans with amino acid substitutions in Fks1 at position Ser645 cannot be successfully treated with micafungin. Antimicrob. Agents Chemother. 55:3075-3083.
20. Spreghini E, et al. 2012. 2011. Comparative analysis of micafungin, caspofungin, and anidulafungin against a difficult-to treat fungal opportunistic pathogen: Candida glabrata. Antimicrob. Agents Chemother. 56:1215-1222.
21. Vale-Silva L, Pinto P, Lopes V, Ramos H, Pinto E. 9 September 2011, posting date. Comparison of the Etest and a rapid flow cytometry-based method with the reference CLSI broth microdilution protocol M27-A3 for the echinocandin susceptibility testing of Candida spp. Eur. J. Clin. Microbiol. Infect. Dis. doi:10.1007/s10096-011-1390-z.
22. Wiederhold NP, Najvar LK, Bocanegra RA, Kirkpatrick WR, Patterson TF. 2011. Caspofungin dose escalation for invasive candidiasis due to resistant Candida albicans . Antimicrob. Agents Chemother. 55:3254-3260.